Results 51 to 60 of about 886,280 (260)

Vascular parkinsonism: what makes it different?

open access: yes, 2011
Vascular parkinsonism (VP) accounts for 2.5–5% of all cases of parkinsonism in various population based and clinical cohort studies. VP develops as a result of ischaemic cerebrovascular disease, so aetiologically it is classified as secondary ...
Kuruvilla, A   +3 more
core   +1 more source

First delirium episode in Parkinson’s disease and parkinsonism: incidence, predictors, and outcomes

open access: yesnpj Parkinson's Disease, 2021
To define the incidence, predictors and prognosis of the first hospital delirium episode in Parkinson’s disease (PD) and atypical parkinsonism (AP), we identified the first hospital episode of delirium after diagnosis in the Parkinsonism Incidence in ...
Samantha Green   +6 more
doaj   +1 more source

Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level

open access: yesAging and Cancer, EarlyView.
This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley   +1 more source

Vascular Disease, Non‐Steroidal Anti‐Inflammatory Drugs and Risk of Parkinson's Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives A history of vascular disease has been shown to be associated with an increased risk of Parkinson's disease, but this may be due to reverse causation. In addition, non‐steroidal anti‐inflammatory drugs are thought to reduce Parkinson's disease risk, but evidence is inconsistent and confounding by prior vascular disease is possible ...
Clare Wotton   +4 more
wiley   +1 more source

血管性帕金森综合征与帕金森病的临床特征及脑白质高信号差异性研究 Differences between Clinical Features and White Matter Hyperintensities between Vascular Parkinsonism and Parkinson′s Disease

open access: yesZhongguo cuzhong zazhi, 2023
目的 研究血管性帕金森综合征(vascular parkinsonism,VP)与帕金森病(Parkinson’s disease,PD)临床特征及脑白质高信号(white matter hyperintensities,WMH)的差异,为研究VP的发病机制提供一定的依据与思路。 方法 根据临床实际,健康受试者人数以1∶2的比例匹配,回顾性筛选符合入排标准的VP患者和年龄、性别、受教育程度与其相匹配的PD患者、健康志愿者,健康志愿者作为健康对照(healthy control,HC)组 ...
陈柏希,王婉仪,詹翠京,高玉元,聂坤,张玉虎,王丽娟
doaj   +1 more source

Alzheimer's Disease Biomarkers Measured by Capillary Blood Collection Versus Venous Plasma and Cerebrospinal Fluid

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Blood biomarkers are increasingly critical for non‐invasive Alzheimer's Disease (AD) diagnostics and research but typically require on‐site processing. Remote point‐of‐care collection methods could enhance biomarker testing in clinical and research settings.
Sara Ho   +9 more
wiley   +1 more source

Monogenic Parkinson's disease and parkinsonism: Clinical phenotypes and frequencies of known mutations. [PDF]

open access: yes, 2013
Mutations in seven genes are robustly associated with autosomal dominant (SNCA, LRRK2, EIF4G1, VPS35) or recessive (parkin/PARK2, PINK1, DJ1/PARK7) Parkinson's disease (PD) or parkinsonism.
Puschmann, Andreas   +2 more
core   +2 more sources

Cerebrospinal Fluid Over Plasma Links Analytes to Cognitive Decline in Older Adults at Risk for Alzheimer's Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To identify inflammatory analytes in cerebrospinal fluid (CSF) and plasma associated with cognitive decline in cognitively normal (CN) older adults at risk for Alzheimer's disease (AD). Methods In a longitudinal study of 118 CN older adults (65–80 years, 54% APOE ε4, 26% preclinical AD), 1331 CSF and 1501 plasma analytes were ...
Jagan A. Pillai   +13 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

Cerebral hemodynamic dysfunction in parkinsonian patients [PDF]

open access: yesMedicinski Glasnik, 2009
Aim The purpose of this investigation was to determine the cerebral hemodynamics in patients withparkinsonism and the influence of hemodynamic dysfunction in developing the lacunar infarcts.Methods Fifty patients with the signs of parkinsonism were ...
Mirjana Vladetić   +3 more
doaj  

Home - About - Disclaimer - Privacy